Transdermal scopolamine, oral meclizine, and placebo in motion sickness

@article{Dahl1984TransdermalSO,
  title={Transdermal scopolamine, oral meclizine, and placebo in motion sickness},
  author={E Dahl and D Offer-Ohlsen and P. E. Lillevold and L. Sandvik},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1984},
  volume={36}
}
The efficacy of transdermal scopolamine, oral meclizine, and placebo in protection against motion sickness was compared in a double‐blind crossover study. Thirty‐six healthy subjects were exposed to motion three times for 90 min in a ship‐motion simulator. Transdermal applications were made and tablets were taken at least 12 and 2 hr before exposure to motion. Transdermal scopolamine provided better protection than placebo or meclizine. Dryness of mouth was the only side effect reported more… 

Transdermal Hyoscine (Scopolamine)

TLDR
Preliminary evidence suggests transdermal hyoscine may offer an effective and conveniently administered alternative for the prevention of motion-induced nausea and vomiting in certain situations, and its therapeutic efficacy may be variable.

Transdermal Scopolamine for Prevention of Motion Sickness

TLDR
TTS-S has proved to be significantly superior to placebo in reducing the incidence and severity of motion sickness by 60–80% and similar intraindividual absorption and sustained clinical efficacy with long-term use of the drug.

Transdermal scopolamine: Effects upon psychological performance and visual functioning at sea

The effects of transdermal scopolamine upon, psychological task performance, subjective feeling state, and visual functioning, were assessed with 28 naval volunteers at sea. The battery of assessment

Effect of Transdermal Scopolamine on Salivation

TLDR
The effect of transdermal scopolamine on salivary flow and composition was analyzed in 21 healthy volunteers and significant positive correlations were found between the placebo rate of flow and both the quantity and percentage decreases in response to transderMAL scopolamines.

Transdermal Scopolamine : Effects upon Psychological Performance and Visual Functioning at Sea

  • A.
  • Psychology
  • 2004
The effects of transdermal scopolamine upon psychological task performance, subjective feeling state, and visual functioning, were assessed with 28 naval volunteers at sea. The battery of assessment

Transdermal scopolamine attenuates methacholine-induced bronchospasm.

The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting

TLDR
Transdermal scopolamine is a promising candidate for the management of PONV in adults as a first line monotherapy or in combination with other drugs and might be helpful in preventing postoperative discharge nausea and vomiting owing to its long-lasting clinical effects.

The Use of Transdermal Scopolamine in the Control of Death Rattle

TLDR
The following two case reports document the use of transdermal scopolamine in the control of death rattle and the care of the patients discussed was in keeping with the agenda of the Palliative Care Housecall Service.

Side effects of transdermal scopolamine.

Vertigo and Motion Sickness. Part II: Pharmacologic Treatment

TLDR
In this article, the pharmacologic agents that are now available for the treatment of vertigo and those agent that are still under study are discussed.

References

SHOWING 1-10 OF 11 REFERENCES

Transdermal scopolamine in the prevention of motion sickness at sea

TLDR
Comparison with placebo indicated that transdermal scopolamine provided protection against motion sickness at a significance level of p = 0.0001 and oral diphenhydrinate at a level of 0.05, and dry mouth, drowsiness, and blurred vision associated with transderMAL scopolamines therapy were minimal.

Effect of transdermally administered scopolamine in preventing motion sickness.

Drugs preventing motion sickness at sea.

TLDR
The incidence of seasickness is shown to decrease with increasing age and also to correlate with a previous history of motion sickness, and from the standpoint of long-time protection afforded by a single dose, Postafene is most promising, since it gives good protection for at least 24 hours.

Transdermal drug administration--a nuisance becomes an opportunity.

TLDR
The number and duration of the episodes of the various EEG stages of sleep in young and older people and the number of tranquillisers and barbiturates prescribed by general practitioners are compared.

Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion.

TLDR
Motion sickness incidence (MSI), defined as the percentage of Ss experiencing vomiting, was greatest at a frequency of 10 CPM (.167 Hz), and for all wave frequencies, MSI increased as a monotonic function of the acceleration level.

Diagnostic criteria for grading the severity of acute motion sickness.

Abstract : New diagnostic criteria are presented for grading the severity of acute motion sickness. They are more suited to clinical application as empirical evaluations than for precise measurement

Chinn HI: Evaluation of drugs for protection against motion sickness aboard transport ships

  • Pharmacol Rev
  • 1956

Drugs used in motion sickness

  • AMA drug evaluations
  • 1977

Transdermally administered scopolamine for prevention

  • 1981

Transdermally administered scopolamine for prevention of motion sickness in a vertical oscillator

  • CLIN PHARMACOL THER
  • 1977